L-dopa (also known as Levodopa) is a medication that helps improve movement and coordination. It works by converting into dopamine in the brain, a chemical that helps control movement. This medication is commonly used to treat various movement disorders. In this trial, it is being studied to help patients with movement difficulties caused by changes in the CTNNB1 gene. The medication aims to improve motor skills and physical function in these patients.

CTNNB1 Syndrome – A rare genetic disorder caused by mutations in the CTNNB1 gene, which affects brain development and function. This condition typically causes developmental delays, intellectual disability, and problems with movement and muscle control. People with this syndrome often experience difficulties with walking, balance, and coordination. The condition also frequently involves speech delays and learning difficulties.

Neurodevelopmental Disorders – A group of conditions that affect brain function and development during early childhood and adolescence. These disorders impact various areas of development including movement, learning, language, and behavior. The conditions in this group typically become apparent during a child’s developmental period and can affect daily functioning. Children with these disorders may experience challenges with physical coordination, communication, attention, and social interactions.